Author(s): Jorge E Cortes, Hagop M Kantarjian, Javier Pinilla-Ibarz, et. al. Abstract: P 603 Session topic: 8. Chronic myeloid leukemia – Clinical Background: Ponatinib is an oral tyrosine kinase inhibitor (TKI) approved for pts with CP-CML or Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other TKI therapy is indicated,...
Pro zobrazení tohoto obsahu je třeba být přihlášen.